At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Cyclophosphamide for Ovarian Cancer and 2 related conditions. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
The goals of this study were to evaluate the efficacy and safety of sequentially blocking the angiogenesis pathway via known antiangiogenic mechanisms, first with bevacizumab and then addition of oral cyclophosphamide upon progression of cancer through bevacizumab. The drugs used in this study were chosen because of their known antiangiogenic properties, tolerability, and anti-ovarian cancer effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedMar 2009
Primary CompletionApr 2010
Study CompletionJan 2014
TodayJul 2026
First PostedMar 5, 2009
Enrollment StartFeb 1, 2009
Primary CompletionApr 1, 2010
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.3 years ago
Interventions
Bevacizumabdrug
Cyclophosphamidedrug